High-throughput genotyping of a common deletion polymorphism disrupting the TRY6 gene and its association with breast cancer risk
Hemminki Kari, Tecza Karolina, Pekala Wioletta and 5 more
BMC Genetics · 2007
doi:10.1186/1471-2156-8-41 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
<p>Abstract</p> <p>Background</p> <p>Copy number polymorphisms caused by genomic rearrangements like deletions, make a significant contribution to the genomic differences between two individuals and may add to disease predisposition. Therefore, genotyping of such deletion polymorphisms in case-control studies could give important insights into risk associations.</p> <p>Results</p> <p>We mapped the breakpoints and developed a fluorescent fragment analysis for a deletion disrupting the <it>TRY6 </it>gene to exemplify a quick and cheap genotyping approach for such structural variants. We showed that the deletion is larger than predicted and encompasses also the pseudogene <it>TRY5</it>. We performed a case-control study to test an association of the <it>TRY6 </it>deletion polymorphism with breast cancer using a single nucleotide polymorphism which is in 100% linkage disequilibrium with the deletion. We did not observe an effect of the deletion on breast cancer risk (OR 1.05, 95% CI 0.71–1.56).</p> <p>Conclusion</p> <p>Although we did not observe an association between the <it>TRY6 </it>deletion polymorphism and breast cancer risk, the identification and investigation of further deletions using the present approach may help to elucidate their effect on disease susceptibility.</p>
Abstract licence: CC BY
References29
29 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.